Atrial Septal Defect Market: Developments Driving Growth

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Atrial Septal Defect Market During The Forecast Period?

The atrial septal defect market has shown significant growth in recent years. It is projected to expand from $4.46 billion in 2025 to $4.81 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be linked to several contributing factors, including enhanced detection of congenital heart defects, increased availability of surgical correction techniques, the expansion of pediatric cardiology services, growing clinical experience with device-based closures, and wider access to diagnostic imaging technologies.

The atrial septal defect market is anticipated to experience substantial growth over the next few years, with its size projected to reach $6.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period is attributable to an increasing adoption of hybrid closure techniques, a rising focus on early intervention in adults, the expansion of minimally invasive cardiac surgery capabilities, continuous innovation in occluder device design, and an increasing demand for long-term follow-up care solutions. Key trends influencing this period include a greater adoption of transcatheter closure devices, a rising preference for minimally invasive repair procedures, the growing utilization of advanced cardiac imaging techniques, the expansion of pediatric and adult atrial septal defect screening programs, and an enhanced focus on long-term patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

What Factors Are Contributing To The Growth Of The Atrial Septal Defect Market?

The increasing occurrence of congenital heart defects (CHD) is anticipated to stimulate the expansion of the atrial septal defect market in the future. Congenital heart defects denote structural irregularities within the heart that exist from birth. The escalating prevalence of congenital heart defects refers to the rising number of individuals diagnosed with these inherent structural heart abnormalities. Atrial septal defect treatment plays a role in managing congenital heart defects by rectifying abnormal blood circulation between the heart’s compartments, thereby enhancing overall heart functionality and reducing associated issues. For instance, according to the British Heart Foundation, a UK-based non-profit organization, there were 2.3 million people in the UK living with congenital heart disease as of September 2025. Furthermore, congenital heart disease defects are detected in at least 1 in 150 births, which means an average of 13 babies each day in the UK, with additional diagnoses occurring later in life. Estimates suggest that 1-2 percent of the population may be affected. Therefore, the widespread presence of congenital heart defects will propel the atrial septal defect market.

Which Segment Categories Are Included In The Atrial Septal Defect Market Segment Analysis?

The atrial septal defect market covered in this report is segmented –

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy

2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry

3) By Product Type: Medical Devices, Pharmaceutical Products

4) By Age Group: Pediatric, Adult

5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users

Subsegments:

1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure

2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients

3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds

4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications

What Trends Are Shaping The Future Of The Atrial Septal Defect Market?

Leading firms within the arterial septal defect market are engaged in the development of advanced devices and are actively pursuing regulatory authorization to expand their availability and utility. Device approval entails securing formal permission or certification for a product, typically from a regulatory body or relevant authority, prior to its legal manufacturing, sale, or use in a particular market or for a specific purpose. For instance, in March 2024, Occlutech GmbH, a Sweden-based specialist provider of minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had granted approval for its Occlutech ASD Occluder and Occlutech Pistol Pusher, intended for treating atrial septal defects (ASD). This authorization signifies a major achievement for the company, which is committed to advancing healthcare worldwide. The Occlutech ASD Occluder is engineered as a lifelong intervention for patients with echocardiography-confirmed defects. It functions as a self-expanding nitinol device featuring two flexible discs that are attached to both sides of the patient’s atrial septum using the Occlutech Pistol Pusher. With this clearance, Occlutech is set to commence commercialization in the US via an exclusive partnership with B. Braun Interventional Systems.

Who Are The Active Companies Shaping The Atrial Septal Defect Market?

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy

Get The Full Atrial Septal Defect Market Report:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

Which Region Is The Top Contributor To The Atrial Septal Defect Market By Share?

North America was the largest region in the atrial septal defect market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Atrial Septal Defect Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

Browse Through More Reports Similar to the Global Atrial Septal Defect Market 2026, By The Business Research Company

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Left Atrial Appendage Closure Device Market Report 2026

https://www.thebusinessresearchcompany.com/report/left-atrial-appendage-closure-device-global-market-report

Atrial Fibrillation Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795